Then Celg buys them, or at least makes an offer. $220.IMHO.
Myself with bios that get sold off, did the fundamental picture change? In this case NO, and to me it's looking really good. So this is when I average down. Seems to work., technicals don't really work.
In hindsight it explains strength.
Actually it sold off on about 1/2 the vol today. Agree with kiddo on options.
Although the analogy is cute, I disagree. I think things are coming together really fast. What are you comparing too. Look at AKAO, yikes, that matches your scenario better. Gono trail completion in August right? Unless you are a day trader, then it would seem slow, trading 2-10 times a day. BTW, my cousin was an astronaut -- Dave Hilmers.
We are battling the selling off of the biotech ETF AGIO is in. Tremendous strength. All from the quarterly update IMHO.
I get the same vibes. CEMP is like a hunk of red meat thrown out in the middle of a hog pin. I will be hard to not have a feeding frenzy.
Good points. More risk here for sure, although AGIO's last update kept me in the stock...sounds like things are going really well, Cowen summed it up. That all said, CELG is my favorite from a risk\reward take.
I left out lung. I am only talking about the IH1m group...Let's just talk prostate, DNDN is just getting Provenge rolling, and earned over $300M, they just started rolling out in Europe. Could easily be a billion + drug. This is just one IDH1m cancer. And there are the IDH2m group of cancers. I think your #'s are way too low. Like I said, I have been wrong before.
Hey I am wrong more than I am right. Do your numbers include cancer metabolisms? Also, do they include prostate, colon, melanoma, liver to name a few. They seem low, if they do.
AGIOS debunked Canaccord. Schooled him politely on an assumption he made on a follow-up question regarding solid tumors.
I think it had more to do with the update. The pipeline is advancing on all fronts exceedingly well. Sounds like solid tumors is too.in so many words I pretty much debunked the Canaccord thesis.after that update I thought, and I am sure those attending, this sounds like they are on to something very very big IMHO.
Most of the investment community won't, can't, etc...deal with an OTC.Co's until they are listed on a major exchange. People like Cramer can't talk about them. Shorting becomes more difficult.